Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22026919 | 0.90 | NAAA (0.46) | ATML3MBTL1NAAAMMP1MMP2 | |
| SCHEMBL22026882 | 0.85 | LMNA (0.45) | ATML3MBTL1NAAAMMP1MMP2 | |
| SCHEMBL25387067 | 0.85 | NAAA (0.52) | ATML3MBTL1NAAASMN1; SMN2ALDH1A1 | |
| SCHEMBL22027277 | 0.85 | DGAT1 (0.46) | ATML3MBTL1NAAAMMP1MMP2 | |
| SCHEMBL22027306 | 0.85 | CA12 (0.40) | CA1CA2MAPTKDM4EKMT2A | |
| SCHEMBL22083804 | 0.84 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL22027167 | 0.84 | PLK1 (0.45) | ATML3MBTL1NAAAMMP1MMP2 | |
| SCHEMBL22027280 | 0.83 | POLB (0.39) | L3MBTL1SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL204803 | 0.83 | CHRM1 (0.39) | SMN1; SMN2ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL1502311 | 0.83 | MEN1 (0.51) | L3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448508-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | ORGANOVO, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023114823-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114823-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220002309-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20220002309-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20200181104-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200181104-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2020-06-11 | — | — | US | disclosed |
| WO-2020061118-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | ATM 3665/4885L3MBTL1 4422/4885NAAA 2999/4885 |
| US-20220002309-A1 | SSAO INHIBITORS AND USES THEREOF | AOX1, AOC2, MAOA | ATM 1181/4885L3MBTL1 4088/4885NAAA 720/4885 |
| US-20200181104-A1 | SSAO INHIBITORS AND USES THEREOF | AOX1, AOC2, MAOA | ATM 1181/4885L3MBTL1 4088/4885NAAA 720/4885 |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | ATM 3665/4885L3MBTL1 4422/4885NAAA 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.